A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

Summary

This was a randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of HSY244 in participants with atrial fibrillation (AF), with and without heart failure (HF).

Timeline

Start

2020-11-30

Primary completion

2022-07-11

Completion

2022-07-11

Outcome

Outcome not reported

Stopped (Business): “Terminated due to business decision”

Drugs

Indications